Novartis’ Cushing’s disease drug shows promising results in trial
EAST HANOVER, N.J. Swiss drug maker Novartis said its investigational drug is the first to show promise in a late-stage clinical trial for Cushing’s disease, a potentially fatal hormonal disorder.
Novartis announced Wednesday that the drug SOM230 (pasireotide) had reduced cortisol levels in patients with Cushing’s disease. The disease results from a benign pituitary tumor that causes the adrenal glands to produce excess cortisol. This can lead to metabolic and cardiovascular problems and death. Results will be presented at the 14th congress of the European Neuroendocrine Association.
“There is a critical need for a medical treatment for people with Cushing’s disease because currently available options, such as surgery or radiotherapy, are ultimately not effective for many of the patients who suffer from this debilitating disease,” said William Ludlam, director of the Seattle Pituitary Center at the Swedish Neuroscience Institute in Seattle. “The results of this study suggest that pasireotide may help patients achieve biochemical control of their Cushing’s disease and its symptoms by directly targeting the pituitary tumor that triggers excess cortisol production.”
Sanofi-Aventis, Paul and Mira Sorvino launch ‘Diabetes Co-Stars’ program
BRIDGEWATER, N.J. Sanofi-Aventis has tapped actors Paul and Mira Sorvino to launch an awareness program aimed to help people living with diabetes and those who support them.
The "Diabetes Co-Stars" program provides family and friends of diabetics with advice on lifestyle choices, healthy cooking, promoting physical activity and treatment options including insulin, Sanofi-Aventis said. DiabetesCoStars.com provides links to the Sanofi-Aventis diabetes social media pages, including Facebook and Twitter.
The website also provides a look into Paul Sorvino’s life with Type 2 diabetes and how he manages his condition. Sorvino was diagnosed in 2006 with the condition, and at the direction of his doctor, he began taking prescription oral diabetes medications, including Sanofi-Aventis’ diabetes drug Lantus. While treatment and lifestyle changes continue to help Sorvino on his diabetes journey, having support from his daughter, Mira, also has helped Sorvino to make the right decisions.
"’Diabetes Co-Stars’ will help inspire people to find support for their diabetes journey," Sorvino said. "After my diagnosis of Type 2 diabetes, I was completely overwhelmed. I realized the importance of learning how to manage the condition, and that I don’t have to do it alone. I also worked with my doctor to discuss lifestyle changes and to find a treatment plan that works for me."
Rite Aid adds mobile text alerts option for Rx reminders
CAMP HILL, Pa. Rite Aid on Tuesday added automatic mobile text alerts to its opted-in contact options to notify patients when their prescriptions are ready, and for refill and pickup reminders. Patients now have the option to receive such messages by text, e-mail or automated phone call.
Customers who “opt in” to the pharmacy alerts system by signing up for the service online also can be notified if there are any issues encountered after they’ve dropped off their prescription.
“This new service greatly enhances our ability to communicate with our patients while using the communication methods they prefer,” stated Robert Thompson, Rite Aid EVP pharmacy. “In addition to convenience, these alerts also help our patients stay current with their prescriptions and improve patient compliance in taking medications as prescribed.”
To receive alerts, patients must have an online MyRiteAid.com account and complete the MyPharmacy online profile.
The addition of text messaging to Rite Aid’s pharmacy alerts program is powered by Sybase 365, the company noted. “According to the Sybase 365 Global Consumer Acceptance and Usage Report released earlier this year, the study found that consumers are looking for more from their phones, with 70% reporting interest in additional mobile services,” said Marty Beard, Sybase 365 president.